aTyr Pharma, Inc.
HISTIDYL-TRNA SYNTHETASE-FC CONJUGATES

Last updated:

Abstract:

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.

Status:
Application
Type:

Utility

Filling date:

10 Jun 2021

Issue date:

31 Mar 2022